Date:1/24/2011

ldwide Neulasta^® (pegfilgrastim) and NEUPOGEN^® (Filgrastim) sales increased 3 percent to $1,237 million in the fourth quarter of 2010 versus $1,202 million in the fourth quarter of 2009.  Combined U.S. Neulasta and NEUPOGEN sales increased 4 percent to $914 million in the fourth quarter of 2010 versus $880 million in the fourth quarter of 2009, primarily driven by an increase in the average net sales price, and to a lesser extent, favorable changes in wholesaler inventories.  Combined Neulasta and NEUPOGEN international sales were $323 million in the fourth quarter of 2010 versus $322 million in the fourth quarter of 2009.  Excluding foreign exchange impact, international Neulasta and NEUPOGEN product sales increased 2 percent, reflecting growth in Neulasta primarily from continued conversion of NEUPOGEN to Neulasta, partially offset by a decline in NEUPOGEN as a result of biosimilar competition. For the year, combined worldwide Neulasta and NEUPOGEN sales increased 4 percent to $4,844 million in 2010 versus $4,643 million in 2009, principally driven by an increase in the U.S. average net sales price, and to a lesser extent, favorable changes in U.S. wholesaler inventories.

Enbrel^® (etanercept) sales increased 3 percent to $939 million in the fourth quarter of 2010 versus $912 million in the fourth quarter 2009. For the year, ENBREL sales increased 1 percent to $3,534 million in 2010 versus $3,493 million in 2009. In the fourth quarter of 2010, the mid single-digit decline in unit demand, due to share declines primarily in dermatology, was offset by an increase in the average net sales price.  ENBREL continues to maintain a leading position in both the rheumatology and dermatology segments.  

Worldwide sales of Sensipar^® / Mimpara^® (cinacalcet) increased 10 percent to $188 million in the fourth quarter of 2010 versus $171 million in the fourth quart
'/>"/>

SOURCE Amgen Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments